Translating therapies for Huntington's disease from genetic animal models to clinical trials.
Genetic animal models of inherited neurological diseases provide an opportunity to test potential treatments and explore their promise for translation to humans experiencing these diseases. Therapeutic trials conducted in mouse models of Huntington's disease have identified a growing number of potential therapies that are candidates for clinical trials. Although it is very exciting to have these candidates, there has been increasing concern about the feasibility and desirability of taking all of the compounds that may work in mice and testing them in patients with HD. There is a need to begin to prioritize leads emerging from transgenic mouse studies; however, it is difficult to compare results between compounds and laboratories, and there are also many additional factors that can affect translation to humans. Among the important issues are what constitutes an informative genetic model, what principals should be followed in designing and conducting experiments using genetic animal models, how can results from different laboratories and in different models be compared, what body of evidence is desirable to fully inform clinical decision making, and what factors contribute to the equipoise in determining whether preclinical information about a therapy makes clinical study warranted. In the context of Huntington's disease, we will review the current state of genetic models and their successes in putting forward therapeutic leads, provide a guide to assessing studies in mouse models, and discuss some of the salient issues related to translation from mice to humans.
Hersch
Steven M
SM
Neurology Service, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA.
Ferrante
Robert J
RJ
D000818:Animals; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy* / Q000235:genetics*; D051379:Mice; D008822:Mice, Transgenic; D008957:Models, Genetic; D018696:Neuroprotective Agents / Q000627:therapeutic use
D018696:Neuroprotective Agents
Behav Brain Res. 1999 Nov 15;105(2):207-17
10563494
Nature. 1999 May 20;399(6733):263-7
10353249
J Neurosci. 2000 Jun 15;20(12):4389-97
10844007
Nat Med. 2000 Jul;6(7):797-801
10888929
Hum Mol Genet. 2001 Jan 15;10(2):137-44
11152661
Ann Intern Med. 2001 Apr 17;134(8):663-94
11304107
Neurosci Lett. 2001 Jun 22;306(1-2):89-92
11403965
Neurobiol Dis. 2001 Jun;8(3):479-91
11447996
Ann Neurol. 2001 Jul;50(1):112-7
11456300
Neurology. 2001 Aug 14;57(3):397-404
11502903
Neuroreport. 2001 Oct 29;12(15):3371-3
11711888
Neurosci Lett. 2001 Nov 27;315(3):149-53
11716985
Nat Med. 2002 Feb;8(2):143-9
11821898
Ann Neurol. 2002 Feb;51(2):235-42
11835380
J Neurosci. 2002 Mar 1;22(5):1592-9
11880489
Hum Mol Genet. 2002 Mar 15;11(6):633-40
11912178
Neuroreport. 2002 Jan 21;13(1):29-33
11924889
Cell Death Differ. 2002 Sep;9(9):873-80
12181738
Mov Disord. 2002 Jul;17(4):748-57
12210870
J Neurosci. 2002 Oct 15;22(20):8942-50
12388601
Nature. 2003 Jan 23;421(6921):373-9
12540902
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2911-6
12589027
J Neurosci. 2003 Mar 15;23(6):2193-202
12657678
Neurology. 2003 Apr 22;60(8):1234-40
12707423
J Neurochem. 2003 Jun;85(6):1359-67
12787055
J Neurochem. 2003 Jul;86(1):267-72
12807446
Hum Mol Genet. 2003 Jul 1;12(13):1555-67
12812983
Ann Neurol. 2003 Aug;54(2):186-96
12891671
J Comp Neurol. 2003 Oct 6;465(1):11-26
12926013
Brain Res Bull. 2003 Sep 30;61(5):469-79
13679245
J Neurosci. 2003 Oct 15;23(28):9418-27
14561870
Nat Biotechnol. 2003 Nov;21(11):1274-9
14595351
Cell. 1996 Nov 1;87(3):493-506
8898202
Nat Genet. 1998 Oct;20(2):198-202
9771716
Hum Mol Genet. 1999 Mar;8(3):397-407
9949199
Hum Mol Genet. 1999 May;8(5):763-74
10196365
Hum Mol Genet. 2000 Mar 1;9(4):503-13
10699173